Therapeutic efficacy evaluation of radioimmunotherapy with 90Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Science"
DOI: 10.1111/cas.13979
Abstract: Podoplanin is a type I transmembrane sialomucin‐like glycoprotein that is highly expressed in malignant mesothelioma. The rat‐human chimeric antibody NZ‐12 has high affinity for human podoplanin and antibody‐dependent cellular cytotoxicity and is applicable for radioimmunotherapy… read more here.
Keywords: 90y labeled; mesothelioma; podoplanin; podoplanin antibody ... See more keywords